Metropolis Healthcare's Big Growth Plan | 15% Revenue Growth, 28% Margin Target | C Surendran
NDTV Profit · 04 Nov 2026 · 8 min
Management interview of Metropolis Healthcare Ltd (METROPOLIS), with 10 key numbers discussed.
- S Surendran, MD & CEO, Metropolis Healthcare Ltd
Metropolis Healthcare delivered 16% revenue growth and a 190 bps EBITDA margin improvement in H1FY27, driven by 20%+ growth in specialty, wellness, and tier-3 segments. Management guided for 16% revenue growth and 180-190 bps margin improvement to continue in H2FY27, with a price revision under consideration for early next year. The company plans no major lab expansion capex over the next 2-3 years, focusing instead on expanding collection centers to boost lab productivity and return ratios. Metropolis holds over Rs 300 cr in cash with zero debt to fund potential acquisitions across North and East India or new testing skill sets.